{"id":1004,"date":"2021-01-10T09:43:11","date_gmt":"2021-01-10T14:43:11","guid":{"rendered":"https:\/\/covidqanda.org\/?p=1004"},"modified":"2021-01-10T09:43:11","modified_gmt":"2021-01-10T14:43:11","slug":"got-any-good-news-yes-treatment-immunity","status":"publish","type":"post","link":"https:\/\/covidqanda.org\/?p=1004","title":{"rendered":"Got any good news? (yes! treatment; immunity)"},"content":{"rendered":"\n

Question:<\/span><\/strong>\u00a0Got any good news?\u00a0<\/p>\n\n\n\n

Answer:\u00a0<\/span><\/strong>Two studies were published in the last few days that offer some good news regarding effective treatment and lasting immunity:<\/p>\n\n\n\n

  1. Effective treatment:<\/span>\u00a0The New England Journal and Medicine <\/em>published this week the results of a randomized controlled study, Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults<\/a>, which showed that if given to older patients<\/strong> (ages 65+) early after symptom onset<\/strong>\u00a0(within 72 hours), convalescent plasma<\/strong> (e.g. blood plasma from people already recovered from COVID) can significantly reduce the risk of severe disease <\/strong>(nearly halving the risk of severe respiratory disease; 48% relative risk reduction among treatment group compared with placebo group).\u00a0 Of the 80 participants who received convalescent plasma, 13 (16%) developed severe disease whereas of the 80 participants who received placebo, 25 (31%) developed severe disease.\u00a0 For this study, severe disease primary endpoints were defined as\u00a0“a respiratory rate of 30 breaths per minute or more, an oxygen saturation of less than 93% while the patient was breathing ambient air, or both.”<\/li>
  2. Lasting immunity:<\/span>\u00a0Science<\/em>\u00a0published this week the results of a longitudinal cohort study,\u00a0Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection<\/a>, which studied SARS-CoV-2 immune memory– antibodies, memory B cells, CD4+ T cells, and CD8+T cells– over time among 188 participants who had recovered from mild, moderate, and severe COVID, including a few participants who recovered from asymptomatic infection. 51 participants provided blood samples at multiple time points, allowing for longitudinal study, and 43 participants provided samples >6 months after symptom onset. Researchers found that 5-8 months post-symptom onset, almost all individuals had SARS-CoV-2 antibodies; memory B cells were detected in almost all COVID-19 cases, with no apparent decline within 5 to 8 months post-infection; and memory T cells declined over time, but were comparable to levels observed after yellow fever immunization. \u00a0Overall, the study shows that “durable immunity against secondary COVID-19 disease is a possibility in most individuals.<\/strong>”\u00a0 \u00a0 \u00a0<\/li><\/ol>\n","protected":false},"excerpt":{"rendered":"

    Question:\u00a0Got any good news?\u00a0 Answer:\u00a0Two studies were published in the last few days that offer some good news regarding effective treatment and lasting immunity: Effective treatment:\u00a0The New England Journal and Medicine published this week the results of a randomized controlled study, Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults, which showed that […]<\/p>\n","protected":false},"author":1,"featured_media":1005,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"nf_dc_page":"","om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_post_was_ever_published":false},"categories":[38,67],"tags":[161],"class_list":["post-1004","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-immunity","category-treatment","tag-plasma","fallback-thumbnail"],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/i0.wp.com\/covidqanda.org\/wp-content\/uploads\/2021\/01\/pexels-photo-3824771.jpeg?fit=1845%2C1300&ssl=1","_links":{"self":[{"href":"https:\/\/covidqanda.org\/index.php?rest_route=\/wp\/v2\/posts\/1004","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/covidqanda.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/covidqanda.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/covidqanda.org\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/covidqanda.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=1004"}],"version-history":[{"count":1,"href":"https:\/\/covidqanda.org\/index.php?rest_route=\/wp\/v2\/posts\/1004\/revisions"}],"predecessor-version":[{"id":1006,"href":"https:\/\/covidqanda.org\/index.php?rest_route=\/wp\/v2\/posts\/1004\/revisions\/1006"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/covidqanda.org\/index.php?rest_route=\/wp\/v2\/media\/1005"}],"wp:attachment":[{"href":"https:\/\/covidqanda.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=1004"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/covidqanda.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=1004"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/covidqanda.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=1004"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}